Constantly worrying about being glutened? You are not alone.
The Solutions for Celiac research study is testing an investigational medication made of two enzymes that potentially target and break down accidentally ingested gluten proteins, making them inactive and less likely to cause symptoms and intestinal damage in people with celiac disease.
You simply stir the investigational medication, which is a powdered drink mix, with water and take it with every meal. It is designed for people who are already on a gluten-free diet and still experience moderate to severe symptoms.
Previous clinical trials involving this investigational treatment showed reduced damage to the intestine and reduced symptoms after a gluten challenge compared to placebo. It is unlike other celiac disease clinical trials that involve uncomfortable biopsies or frequent injections.
- Are between 18 and 80 years old
- Have a biopsy confirmed diagnosis of celiac disease
- Have been on a gluten-free diet for the last 12 months
- Have experienced at least one moderate or greater severity symptom of abdominal pain and/or bloating in the last month
- Are not pregnant or actively looking to become pregnant
- Are willing to travel to your respective study site for up to 6 visits
- No uncomfortable biopsies or injections
- All study procedures and medication provided at no cost
- Compensation up to $1300
- Travel reimbursement may cover mileage and/or certain airfare, transfer, and hotels
Study Site Locations:
- Mayo Clinic (Rochester, MN)
- Columbia University (New York, NY)
- ClinSearch (Chattanooga, TN)
- Clinical Research Institute of Michigan (Detroit Metro, MI)
- Harvard Beth Israel Deaconess Medical Center (Boston, MA)
- Stanford Medical Center (Palo Alto, CA)
- University of Chicago (Chicago, IL)
Join the Solutions for Celiac clinical trial to see if our drinkable study medication, latiglutenase, can help reduce the symptoms of being glutened.
Learn more and see if you qualify:
About the Study Sponsor
ImmunogenX, Inc. is a clinical-stage biotherapeutics company founded in 2013 and is supported by a team of world-renowned clinicians, scientists and advisors in celiac disease research. The company is developing Latiglutenase (IMGX003) for celiac disease therapy. ImmunogenX is also developing a minimally-invasive diagnostic tool for celiac disease management (CypCelTM) based on a clinically relevant metabolic marker compound that can assess the state of recovery of a celiac patient adhering to a gluten-free diet or other treatment.